MSCV-BCL6-t2A-BCL2 Citations (3)
Originally described in: Genetic modification of primary human B cells to model high-grade lymphoma.Caeser R, Di Re M, Krupka JA, Gao J, Lara-Chica M, Dias JML, Cooke SL, Fenner R, Usheva Z, Runge HFP, Beer PA, Eldaly H, Pak HK, Park CS, Vassiliou GS, Huntly BJP, Mupo A, Bashford-Rogers RJM, Hodson DJ Nat Commun. 2019 Oct 4;10(1):4543. doi: 10.1038/s41467-019-12494-x. PubMed Journal
Articles Citing MSCV-BCL6-t2A-BCL2
| Articles |
|---|
| BTG1 mutation yields supercompetitive B cells primed for malignant transformation. Mlynarczyk C, Teater M, Pae J, Chin CR, Wang L, Arulraj T, Barisic D, Papin A, Hoehn KB, Kots E, Ersching J, Bandyopadhyay A, Barin E, Poh HX, Evans CM, Chadburn A, Chen Z, Shen H, Isles HM, Pelzer B, Tsialta I, Doane AS, Geng H, Rehman MH, Melnick J, Morgan W, Nguyen DTT, Elemento O, Kharas MG, Jaffrey SR, Scott DW, Khelashvili G, Meyer-Hermann M, Victora GD, Melnick A. Science. 2023 Jan 20;379(6629):eabj7412. doi: 10.1126/science.abj7412. Epub 2023 Jan 20. PubMed |
A platform to induce and mature biomolecular condensates using chemicals and light.
Hernandez-Candia CN, Brady BR, Harrison E, Tucker CL.
Nat Chem Biol. 2024 Jan 8. doi: 10.1038/s41589-023-01520-1.
PubMed
Associated Plasmids |
| Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes. Dreute J, Stengel J, Becher J, van den Borre D, Pfisterer M, Bartkuhn M, Beutgen VM, Ndreshkjana B, Gartner U, Graumann J, Huck M, Klatt S, Leff C, Farin HF, Nist A, Schmitz R, Stiewe T, Teply-Szymanski J, Wilhelm J, Cabrera-Orefice A, Schmitz ML. Cell Death Differ. 2025 Jun 23. doi: 10.1038/s41418-025-01532-5. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.